Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
Plasma levels of urokinase-type plasminogen activator have been investigated in 80 patients with prostatic carcinoma by means of a radioimmunoassay. A total of 30 patients with disseminated prostatic carcinoma had significantly elevated levels of urokinase-type plasminogen activator, whereas the plasma levels in patients without metastases did not differ from a healthy age matched control group. Sensitivity of elevated urokinase-type plasminogen activator levels in patients with prostatic carcinoma for the presence of metastases was 80 per cent. Therefore, urokinase-type plasminogen activator appears to be a reliable marker for the formation of metastases in prostatic carcinoma.
Hienert
G
G
Department of Urology, University of Vienna, Austria.
Kirchheimer
J C
JC
Pflüger
H
H
Binder
B R
BR
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D002277:Carcinoma / Q000097:blood* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D011863:Radioimmunoassay; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood*
D014408:Biomarkers, Tumor; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D014568:Urokinase-Type Plasminogen Activator